Literature DB >> 11152306

National survey of hepatitis testing and vaccination services provided by drug services in England and Wales.

A R Winstock1, J Sheridan, S Lovell, M Farrell, J Strang.   

Abstract

Since viral hepatitis among intravenous drug users continues to be a major cause of morbidity and mortality, the present study was conducted to survey drug agencies in England and Wales in order to identify the prevalence of hepatitis B and C testing and vaccination being provided. A postal survey of all 539 drug agencies in England and Wales was thus conducted to assess their current treatment provisions and practices. An analysis of the responses provided by the 373 agencies that returned usable data (69.2% response rate) revealed that only one-quarter (26.6%) of the drug agencies conducted routine hepatitis B testing, and 26.9% did not offer it at all. Just over half (55.7%) of the agencies provided hepatitis B vaccination, but only 21.7% did so routinely. Seventy percent provided hepatitis C testing, but only 24% did so routinely. Nevertheless, the majority of respondents, of whom 40.3% were nurses and 25.1% drug workers, believed that clients and their partners should be offered hepatitis B and C screening. The paucity of hepatitis testing and vaccination services being offered to injecting drug users is unacceptable, with users, their partners and children being needlessly exposed to continued risk. The disparity between recommended policy and current practice needs to be urgently addressed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152306     DOI: 10.1007/s100960000377

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  High risk groups are still not being vaccinated.

Authors:  Adam R Winstock
Journal:  BMJ       Date:  2005-01-22

2.  Hepatitis B vaccination and injecting drug users.

Authors:  John Budd; Roy Robertson; Rob Elton
Journal:  Br J Gen Pract       Date:  2004-06       Impact factor: 5.386

Review 3.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.